Nestle Health Science
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nestle Health Science
Palforzia will almost certainly be the first treatment to get the green light for peanut allergy in Europe and its new owner will be hoping for a more successful launch than has been seen in the US.
HBW Product Launches: Blue Light Defender Kids, TruNiagen In Celltrient, Velositol In Outright, More
Viteyes responds to pandemic; ChromaDex’ TruNiagen in Nestle Celltrient line extension; 7-Eleven goes sugar-free in energy with Triton; Nutrition21’s Velositol in MTS Outright Bar; Bhu Foods keto bars In Target, Walmart.
Consumer health companies are starting to step into the lucrative but fast-changing and complex EU cannabidiol market. But what are the key considerations for firms before making such a move, or if they have already? HBW Insight speaks to CBD regulatory expert Greer Deal.
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
- Medical Devices
- OTC, Consumer
- Other Names / Subsidiaries
- Prometheus Laboratories, Inc., Nestle S.A., Aimmune Therapeutics, Inc.